Bausch Health. has filed a patent for novel guanylate cyclase-C agonist peptides for treating gastrointestinal disorders, inflammation, and cancer. The method includes administering the peptide of SEQ ID NO: 9, classified as a (4,12:7,15) bicycle, to treat cancer in a subject. GlobalData’s report on Bausch Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bausch Health Companies Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bausch Health, Cancer treatment biomarkers was a key innovation area identified from patents. Bausch Health's grant share as of January 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of cancer using guanylate cyclase-c agonist peptides

Source: United States Patent and Trademark Office (USPTO). Credit: Bausch Health Companies Inc

A recently filed patent (Publication Number: US20240002440A1) discloses a method for treating cancer in a subject by administering a composition containing a specific peptide (SEQ ID NO: 9) that is a (4,12:7,15) bicycle. The method involves administering a therapeutically effective amount of the peptide, with the effective amount ranging from 1 mg to 10 mg per dose. The composition is to be administered once daily to the subject.

Furthermore, the patent claims that the method can be enhanced by administering an inhibitor of cGMP-specific phosphodiesterase (cGMP-PDE) along with the peptide composition. The inhibitor of cGMP-PDE can be administered concurrently or sequentially with the peptide and may include compounds such as sulindac sulfone, zaprinast, motapizone, vardenafil, or sildenafil. Specifically, the inhibitor of cGMP-PDE may comprise sulindac sulfone or zaprinast to achieve the desired therapeutic effect in treating cancer in the subject.

To know more about GlobalData’s detailed insights on Bausch Health, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies